Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients

Ying Cheng Chiang, Ming Cheng Chang, Pao Jen Chen, Meei Maan Wu, Chang-Yao Hsieh, Wen Fang Cheng, Chi An Chen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Epithelial ovarian carcinoma is usually present at the advanced stage, during which the patients generally have poor prognosis. Our study aimed to evaluate the correlation of gene methylation and the clinical outcome of patients with advanced-stage, high-grade ovarian serous carcinoma. The methylation status of eight candidate genes was first evaluated by methylation-specific PCR and capillary electrophoresis to select three potential genes including DAPK, CDH1, and BLU (ZMYND10) from the exercise group of 40 patients. The methylation status of these three genes was further investigated in the validation group consisting of 136 patients. Patients with methylated BLU had significantly shorter progression-free survival (PFS; hazard ratio (HR) 1.48, 95% CI 1.01-2.56, PZ0.013) and overall survival (OS; HR 1.83, 95% CI 1.07-3.11, PZ0.027) in the multivariate analysis. Methylation of BLU was also an independent risk factor for 58 patients undergoing optimal debulking surgery for PFS (HR 2.37, 95% CI 1.03-5.42, PZ0.043) and OS (HR 3.96, 95% CI 1.45-10.81, PZ0.007) in the multivariate analysis. A possible mechanism of BLU in chemoresistance was investigated in ovarian cancer cell lines by in vitro apoptotic assays. In vitro studies have shown that BLU could upregulate the expression of BAX and enhance the effect of paclitaxel-induced apoptosis in ovarian cancer cells. Our study suggested that methylation of BLU could be a potential prognostic biomarker for advanced ovarian serous carcinoma.

Original languageEnglish
Pages (from-to)213-227
Number of pages15
JournalEndocrine-Related Cancer
Volume20
Issue number2
DOIs
Publication statusPublished - Apr 2013
Externally publishedYes

Fingerprint

Epigenomics
Methylation
Apoptosis
Carcinoma
Ovarian Neoplasms
Genes
Multivariate Analysis
Capillary Electrophoresis
Paclitaxel
Disease-Free Survival
Up-Regulation
Biomarkers
Exercise
Cell Line
Polymerase Chain Reaction
Survival

Keywords

  • Apoptosis
  • BLU
  • Gene methylation
  • Ovarian carcinoma
  • Paclitaxel

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Cite this

Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients. / Chiang, Ying Cheng; Chang, Ming Cheng; Chen, Pao Jen; Wu, Meei Maan; Hsieh, Chang-Yao ; Cheng, Wen Fang; Chen, Chi An.

In: Endocrine-Related Cancer, Vol. 20, No. 2, 04.2013, p. 213-227.

Research output: Contribution to journalArticle

Chiang, Ying Cheng ; Chang, Ming Cheng ; Chen, Pao Jen ; Wu, Meei Maan ; Hsieh, Chang-Yao ; Cheng, Wen Fang ; Chen, Chi An. / Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients. In: Endocrine-Related Cancer. 2013 ; Vol. 20, No. 2. pp. 213-227.
@article{cbad376091e94f10b2b3afe6c20ea750,
title = "Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients",
abstract = "Epithelial ovarian carcinoma is usually present at the advanced stage, during which the patients generally have poor prognosis. Our study aimed to evaluate the correlation of gene methylation and the clinical outcome of patients with advanced-stage, high-grade ovarian serous carcinoma. The methylation status of eight candidate genes was first evaluated by methylation-specific PCR and capillary electrophoresis to select three potential genes including DAPK, CDH1, and BLU (ZMYND10) from the exercise group of 40 patients. The methylation status of these three genes was further investigated in the validation group consisting of 136 patients. Patients with methylated BLU had significantly shorter progression-free survival (PFS; hazard ratio (HR) 1.48, 95{\%} CI 1.01-2.56, PZ0.013) and overall survival (OS; HR 1.83, 95{\%} CI 1.07-3.11, PZ0.027) in the multivariate analysis. Methylation of BLU was also an independent risk factor for 58 patients undergoing optimal debulking surgery for PFS (HR 2.37, 95{\%} CI 1.03-5.42, PZ0.043) and OS (HR 3.96, 95{\%} CI 1.45-10.81, PZ0.007) in the multivariate analysis. A possible mechanism of BLU in chemoresistance was investigated in ovarian cancer cell lines by in vitro apoptotic assays. In vitro studies have shown that BLU could upregulate the expression of BAX and enhance the effect of paclitaxel-induced apoptosis in ovarian cancer cells. Our study suggested that methylation of BLU could be a potential prognostic biomarker for advanced ovarian serous carcinoma.",
keywords = "Apoptosis, BLU, Gene methylation, Ovarian carcinoma, Paclitaxel",
author = "Chiang, {Ying Cheng} and Chang, {Ming Cheng} and Chen, {Pao Jen} and Wu, {Meei Maan} and Chang-Yao Hsieh and Cheng, {Wen Fang} and Chen, {Chi An}",
year = "2013",
month = "4",
doi = "10.1530/ERC-12-0117",
language = "English",
volume = "20",
pages = "213--227",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "2",

}

TY - JOUR

T1 - Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients

AU - Chiang, Ying Cheng

AU - Chang, Ming Cheng

AU - Chen, Pao Jen

AU - Wu, Meei Maan

AU - Hsieh, Chang-Yao

AU - Cheng, Wen Fang

AU - Chen, Chi An

PY - 2013/4

Y1 - 2013/4

N2 - Epithelial ovarian carcinoma is usually present at the advanced stage, during which the patients generally have poor prognosis. Our study aimed to evaluate the correlation of gene methylation and the clinical outcome of patients with advanced-stage, high-grade ovarian serous carcinoma. The methylation status of eight candidate genes was first evaluated by methylation-specific PCR and capillary electrophoresis to select three potential genes including DAPK, CDH1, and BLU (ZMYND10) from the exercise group of 40 patients. The methylation status of these three genes was further investigated in the validation group consisting of 136 patients. Patients with methylated BLU had significantly shorter progression-free survival (PFS; hazard ratio (HR) 1.48, 95% CI 1.01-2.56, PZ0.013) and overall survival (OS; HR 1.83, 95% CI 1.07-3.11, PZ0.027) in the multivariate analysis. Methylation of BLU was also an independent risk factor for 58 patients undergoing optimal debulking surgery for PFS (HR 2.37, 95% CI 1.03-5.42, PZ0.043) and OS (HR 3.96, 95% CI 1.45-10.81, PZ0.007) in the multivariate analysis. A possible mechanism of BLU in chemoresistance was investigated in ovarian cancer cell lines by in vitro apoptotic assays. In vitro studies have shown that BLU could upregulate the expression of BAX and enhance the effect of paclitaxel-induced apoptosis in ovarian cancer cells. Our study suggested that methylation of BLU could be a potential prognostic biomarker for advanced ovarian serous carcinoma.

AB - Epithelial ovarian carcinoma is usually present at the advanced stage, during which the patients generally have poor prognosis. Our study aimed to evaluate the correlation of gene methylation and the clinical outcome of patients with advanced-stage, high-grade ovarian serous carcinoma. The methylation status of eight candidate genes was first evaluated by methylation-specific PCR and capillary electrophoresis to select three potential genes including DAPK, CDH1, and BLU (ZMYND10) from the exercise group of 40 patients. The methylation status of these three genes was further investigated in the validation group consisting of 136 patients. Patients with methylated BLU had significantly shorter progression-free survival (PFS; hazard ratio (HR) 1.48, 95% CI 1.01-2.56, PZ0.013) and overall survival (OS; HR 1.83, 95% CI 1.07-3.11, PZ0.027) in the multivariate analysis. Methylation of BLU was also an independent risk factor for 58 patients undergoing optimal debulking surgery for PFS (HR 2.37, 95% CI 1.03-5.42, PZ0.043) and OS (HR 3.96, 95% CI 1.45-10.81, PZ0.007) in the multivariate analysis. A possible mechanism of BLU in chemoresistance was investigated in ovarian cancer cell lines by in vitro apoptotic assays. In vitro studies have shown that BLU could upregulate the expression of BAX and enhance the effect of paclitaxel-induced apoptosis in ovarian cancer cells. Our study suggested that methylation of BLU could be a potential prognostic biomarker for advanced ovarian serous carcinoma.

KW - Apoptosis

KW - BLU

KW - Gene methylation

KW - Ovarian carcinoma

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=84876779879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876779879&partnerID=8YFLogxK

U2 - 10.1530/ERC-12-0117

DO - 10.1530/ERC-12-0117

M3 - Article

VL - 20

SP - 213

EP - 227

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 2

ER -